Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 360

1.

Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?

Madariaga A, Goodwin PJ, Oza AM.

Clin Cancer Res. 2019 Nov 26. pii: clincanres.3645.2019. doi: 10.1158/1078-0432.CCR-19-3645. [Epub ahead of print]

PMID:
31772118
2.

Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.

Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA.

Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404. doi: 10.1136/ijgc-2019-000623.

PMID:
31685558
3.

Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer.

Lee YC, Jivraj N, Wang L, Chawla T, Lau J, Croke J, Allard JP, Stuart-McEwan T, Nathwani K, Bowering V, Karakasis K, O'Brien C, Shlomovitz E, Ferguson SE, Buchanan S, Ng P, Cyriac S, Tinker L, Dhani N, Oza AM, Lheureux S.

J Oncol Pract. 2019 Sep 24:JOP1800793. doi: 10.1200/JOP.18.00793. [Epub ahead of print]

PMID:
31550202
4.

Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study.

Korach J, Colombo N, Mendiola C, Selle F, Dolado I, Donica M, Oza AM.

J Surg Oncol. 2019 Sep;120(4):786-793. doi: 10.1002/jso.25647. Epub 2019 Jul 31.

PMID:
31368160
5.

Precursor reaction kinetics control compositional grading and size of CdSe1-x S x nanocrystal heterostructures.

Hamachi LS, Yang H, Jen-La Plante I, Saenz N, Qian K, Campos MP, Cleveland GT, Rreza I, Oza A, Walravens W, Chan EM, Hens Z, Crowther AC, Owen JS.

Chem Sci. 2019 Jun 5;10(26):6539-6552. doi: 10.1039/c9sc00989b. eCollection 2019 Jul 14.

6.

Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing.

Garg S, Nagaria TS, Clarke B, Freedman O, Khan Z, Schwock J, Bernardini MQ, Oza AM, Han K, Smith AC, Stockley TL, Rouzbahman M.

Mod Pathol. 2019 Dec;32(12):1823-1833. doi: 10.1038/s41379-019-0305-x. Epub 2019 Jul 15.

PMID:
31308508
7.

Targeting TGFβ Pathway in Adult Granulosa Cell Tumor: Opening Pandora's Box?

Bonilla L, Oza AM.

Clin Cancer Res. 2019 Sep 15;25(18):5432-5434. doi: 10.1158/1078-0432.CCR-19-1605. Epub 2019 Jul 11.

PMID:
31296528
8.

Prenatal cytogenomic identification and molecular refinement of compound heterozygous STRC deletion breakpoints.

Shi L, Bai Y, Kharbutli Y, Oza AM, Amr SS, Edelmann L, Mehta L, Scott SA.

Mol Genet Genomic Med. 2019 Aug;7(8):e806. doi: 10.1002/mgg3.806. Epub 2019 Jun 19.

9.

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.

Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR.

J Clin Oncol. 2019 Nov 10;37(32):2968-2973. doi: 10.1200/JCO.18.02238. Epub 2019 Jun 7.

PMID:
31173551
10.

Consensus interpretation of the p.Met34Thr and p.Val37Ile variants in GJB2 by the ClinGen Hearing Loss Expert Panel.

Shen J, Oza AM, Del Castillo I, Duzkale H, Matsunaga T, Pandya A, Kang HP, Mar-Heyming R, Guha S, Moyer K, Lo C, Kenna M, Alexander JJ, Zhang Y, Hirsch Y, Luo M, Cao Y, Wai Choy K, Cheng YF, Avraham KB, Hu X, Garrido G, Moreno-Pelayo MA, Greinwald J, Zhang K, Zeng Y, Brownstein Z, Basel-Salmon L, Davidov B, Frydman M, Weiden T, Nagan N, Willis A, Hemphill SE, Grant AR, Siegert RK, DiStefano MT, Amr SS, Rehm HL, Abou Tayoun AN; ClinGen Hearing Loss Working Group.

Genet Med. 2019 Nov;21(11):2442-2452. doi: 10.1038/s41436-019-0535-9. Epub 2019 Jun 4.

PMID:
31160754
11.

High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.

Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C.

Cancer. 2019 Aug 15;125(16):2772-2781. doi: 10.1002/cncr.32079. Epub 2019 Jun 2.

12.

Correction: ClinGen expert clinical validity curation of 164 hearing loss gene-disease pairs.

DiStefano MT, Hemphill SE, Oza AM, Siegert RK, Grant AR, Hughes MY, Cushman BJ, Azaiez H, Booth KT, Chapin A, Duzkale H, Matsunaga T, Shen J, Zhang W, Kenna M, Schimmenti LA, Tekin M, Rehm HL, Tayoun ANA, Amr SS; ClinGen Hearing Loss Clinical Domain Working Group.

Genet Med. 2019 Oct;21(10):2409. doi: 10.1038/s41436-019-0553-7.

PMID:
31114025
13.

FIGO 2018 stage IB2 (2-4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter study.

Plante M, van Trommel N, Lheureux S, Oza AM, Wang L, Sikorska K, Ferguson SE, Han K, Amant F.

Int J Gynecol Cancer. 2019 Jun;29(5):969-975. doi: 10.1136/ijgc-2019-000398. Epub 2019 May 17.

PMID:
31101688
14.

Epithelial ovarian cancer: Evolution of management in the era of precision medicine.

Lheureux S, Braunstein M, Oza AM.

CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17. Review.

15.

Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.

Madariaga A, Rustin GJS, Buckanovich RJ, Trent JC, Oza AM.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e152-e166. doi: 10.1200/EDBK_238755. Epub 2019 May 17. Review.

16.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.

Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

PMID:
30948273
17.

Epithelial ovarian cancer.

Lheureux S, Gourley C, Vergote I, Oza AM.

Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2. Review.

PMID:
30910306
18.

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.

Madariaga A, Lheureux S, Oza AM.

Cancers (Basel). 2019 Mar 23;11(3). pii: E416. doi: 10.3390/cancers11030416. Review.

19.

ClinGen expert clinical validity curation of 164 hearing loss gene-disease pairs.

DiStefano MT, Hemphill SE, Oza AM, Siegert RK, Grant AR, Hughes MY, Cushman BJ, Azaiez H, Booth KT, Chapin A, Duzkale H, Matsunaga T, Shen J, Zhang W, Kenna M, Schimmenti LA, Tekin M, Rehm HL, Tayoun ANA, Amr SS; ClinGen Hearing Loss Clinical Domain Working Group.

Genet Med. 2019 Oct;21(10):2239-2247. doi: 10.1038/s41436-019-0487-0. Epub 2019 Mar 21. Erratum in: Genet Med. 2019 May 22;:.

PMID:
30894701
20.

Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.

Bagnoli M, Shi TY, Gourley C, Speiser P, Reuss A, Nijman HW, Creutzberg CL, Scholl S, Negrouk A, Brady MF, Hasegawa K, Oda K, McNeish IA, Kohn EC, Oza AM, MacKay H, Millan D, Bennett K, Scott C, Mezzanzanica D.

Cells. 2019 Feb 26;8(3). pii: E200. doi: 10.3390/cells8030200. Review.

21.

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM.

Gynecol Oncol. 2019 May;153(2):304-311. doi: 10.1016/j.ygyno.2019.02.005. Epub 2019 Feb 18.

PMID:
30792002
22.

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.

Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX.

J Natl Compr Canc Netw. 2019 Feb;17(2):141-147. doi: 10.6004/jnccn.2018.7094.

23.

Conservative management of adnexal masses.

May T, Oza A.

Lancet Oncol. 2019 Mar;20(3):326-327. doi: 10.1016/S1470-2045(18)30939-2. Epub 2019 Feb 5. No abstract available.

PMID:
30737138
24.

TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses.

Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, Karakasis K, Wang L, Dhani NC, Butler MO, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, Jurisica I, Oza AM, Lheureux S.

Int J Gynecol Cancer. 2019 Jan 18. pii: ijgc-2018-000087. doi: 10.1136/ijgc-2018-000087. [Epub ahead of print]

PMID:
30659026
25.

Advances in prediction for ovarian cancer treatment stratification.

Oza AM.

Nat Rev Clin Oncol. 2019 Feb;16(2):75-76. doi: 10.1038/s41571-018-0147-3. No abstract available.

PMID:
30568177
26.

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.

González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators.

Gynecol Oncol. 2019 Jan;152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. Epub 2018 Nov 16.

27.

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.

Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.

28.

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.

Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK.

Clin Cancer Res. 2019 Mar 15;25(6):1727-1736. doi: 10.1158/1078-0432.CCR-18-2474. Epub 2018 Nov 9.

PMID:
30413525
29.

Targeting Angiogenesis: Taming the Medusa of Ovarian Cancer.

Dhani NC, Oza AM.

Hematol Oncol Clin North Am. 2018 Dec;32(6):1041-1055. doi: 10.1016/j.hoc.2018.07.008. Review.

PMID:
30390759
30.

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.

Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM.

Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.

31.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.

N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.

PMID:
30345884
32.

Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss.

Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, Shen J, Chapin A, Boczek NJ, Schimmenti LA, Murry JB, Hasadsri L, Nara K, Kenna M, Booth KT, Azaiez H, Griffith A, Avraham KB, Kremer H, Rehm HL, Amr SS, Abou Tayoun AN; ClinGen Hearing Loss Clinical Domain Working Group.

Hum Mutat. 2018 Nov;39(11):1593-1613. doi: 10.1002/humu.23630.

33.

Hydrodynamic spin states.

Oza AU, Rosales RR, Bush JWM.

Chaos. 2018 Sep;28(9):096106. doi: 10.1063/1.5034134.

PMID:
30278617
34.

Moving From Mutation to Actionability.

Colombo I, Kurnit KC, Westin SN, Oza AM.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:495-503. doi: 10.1200/EDBK_199665. Review.

35.

Equilibrium Shapes and Their Stability for Liquid Films in Fast Flows.

Ganedi L, Oza AU, Shelley M, Ristroph L.

Phys Rev Lett. 2018 Aug 31;121(9):094501. doi: 10.1103/PhysRevLett.121.094501.

PMID:
30230866
36.

Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion.

Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, Harrison SM; ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI).

Hum Mutat. 2018 Nov;39(11):1517-1524. doi: 10.1002/humu.23626. Epub 2018 Sep 7.

37.

A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.

Lheureux S, Tinker A, Clarke B, Ghatage P, Welch S, Weberpals JI, Dhani NC, Butler MO, Tonkin K, Tan Q, Tan DSP, Brooks K, Ramsahai J, Wang L, Pham NA, Shaw PA, Tsao MS, Garg S, Stockley T, Oza AM.

Clin Cancer Res. 2018 Dec 15;24(24):6168-6174. doi: 10.1158/1078-0432.CCR-18-1244. Epub 2018 Aug 14.

PMID:
30108107
38.

Curating Clinically Relevant Transcripts for the Interpretation of Sequence Variants.

DiStefano MT, Hemphill SE, Cushman BJ, Bowser MJ, Hynes E, Grant AR, Siegert RK, Oza AM, Gonzalez MA, Amr SS, Rehm HL, Abou Tayoun AN.

J Mol Diagn. 2018 Nov;20(6):789-801. doi: 10.1016/j.jmoldx.2018.06.005. Epub 2018 Aug 8.

39.

Additional germline findings from a tumor profiling program.

Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH.

BMC Med Genomics. 2018 Aug 9;11(1):65. doi: 10.1186/s12920-018-0383-5.

40.

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.

Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR.

Lancet Oncol. 2018 Aug;19(8):1117-1125. doi: 10.1016/S1470-2045(18)30333-4. Epub 2018 Jul 17.

PMID:
30026000
41.

Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective.

Lee YC, Jivraj N, O'Brien C, Chawla T, Shlomovitz E, Buchanan S, Lau J, Croke J, Allard JP, Dhar P, Laframboise S, Ferguson SE, Dhani N, Butler M, Ng P, Stuart-McEwan T, Savage P, Tinker L, Oza AM, Lheureux S.

Obstet Gynecol Int. 2018 May 17;2018:1867238. doi: 10.1155/2018/1867238. eCollection 2018. Review.

42.

The role of niraparib for the treatment of ovarian cancer.

Ethier JL, Lheureux S, Oza AM.

Future Oncol. 2018 Oct;14(25):2565-2577. doi: 10.2217/fon-2018-0101. Epub 2018 Jun 1. Review.

PMID:
29856239
43.

Statin use and mortality in gout: A general population-based cohort study.

Keller SF, Rai SK, Lu N, Oza A, Jorge AM, Zhang Y, Choi HK.

Semin Arthritis Rheum. 2018 Dec;48(3):449-455. doi: 10.1016/j.semarthrit.2018.03.007. Epub 2018 Mar 17.

PMID:
29801703
44.

Analysis of intragenic USH2A copy number variation unveils broad spectrum of unique and recurrent variants.

Austin-Tse CA, Mandelker DL, Oza AM, Mason-Suares H, Rehm HL, Amr SS.

Eur J Med Genet. 2018 Oct;61(10):621-626. doi: 10.1016/j.ejmg.2018.04.006. Epub 2018 Apr 12.

PMID:
29655801
45.

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.

Colombo I, Lheureux S, Oza AM.

Drug Des Devel Ther. 2018 Mar 21;12:605-617. doi: 10.2147/DDDT.S130809. eCollection 2018. Review.

46.

Emerging growth factor receptor antagonists for ovarian cancer treatment.

Bonilla L, Oza A, Lheureux S.

Expert Opin Emerg Drugs. 2018 Mar;23(1):1-16. doi: 10.1080/14728214.2018.1446942. Epub 2018 Mar 12. Review.

PMID:
29528256
47.

Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study.

Selle F, Colombo N, Korach J, Mendiola C, Cardona A, Ghazi Y, Oza AM.

Int J Gynecol Cancer. 2018 May;28(4):729-737. doi: 10.1097/IGC.0000000000001221.

PMID:
29498983
48.

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.

Oza A, Kaye S, Van Tornout J, Sessa C, Gore M, Naumann RW, Hirte H, Colombo N, Chen J, Gorla S, Poondru S, Singh M, Steinberg J, Yuen G, Banerjee S.

Gynecol Oncol. 2018 May;149(2):275-282. doi: 10.1016/j.ygyno.2018.01.019. Epub 2018 Feb 14.

49.

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.

Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ.

Future Oncol. 2018 Jul;14(17):1669-1678. doi: 10.2217/fon-2017-0646. Epub 2018 Feb 9.

50.

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.

Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF.

Ann Oncol. 2018 Apr 1;29(4):917-923. doi: 10.1093/annonc/mdy023.

PMID:
29401246

Supplemental Content

Support Center